Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like ...

Explore Alnylam Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for ALNY. Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff ...

The Food and Drug Administration cleared Alnylam Pharmaceuticals’ treatment for a progressive heart condition Thursday, setting it up to compete with therapies from BridgeBio and Pfizer.

Shares in Alnylam were up almost 56% at one point yesterday, while rival Ionis saw its shares slump 9%. Shares in The Medicines Company were also up 5.7% thanks to an RNAi licensing deal with Alnylam.

Alnylam Pharmaceuticals (ALNY) shares rallied 8.5% in the last trading session to close at $243.27. This move can be attributable to notable volume with a higher number of shares being traded than ...

Alnylam's Amvuttra first to treat both nerve and heart forms of ATTR-CM Pricing strategy crucial for Amvuttra's market share against oral options Alnylam is banking on the success of the drug ...

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of ...

Alnylam already markets the medicine for people with a form of the condition that affects the nerves, but has long looked to an approval in cardiomyopathy as the kind of revenue driver that can ...

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated ...

Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major milestone — finally reaching profitability. Alnylam Pharmaceuticals ...